Skip to main content
Marc Lener, MD, Psychiatry, New York, NY

Marc Lener MD


Chief Executive Officer and Director of Singula Institute

Join to View Full Profile
  • 353 Lexington AvenueRoom 600New York, NY 10016

  • Phone+1 240-389-2381

  • Fax+1 240-389-2381

Dr. Lener is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Clinical Center at the National Institutes of Health
    Clinical Center at the National Institutes of HealthFellowship, National Institute of Mental Health, 2015 - 2018
  • Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Psychiatry, 2011 - 2015
  • George Washington University School of Medicine and Health Sciences
    George Washington University School of Medicine and Health SciencesClass of 2011
  • University of Pennsylvania
    University of PennsylvaniaB.A., Biological Basis of Behavior, 1996 - 2000

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2015 - 2026
  • NY State Medical License
    NY State Medical License 2013 - 2025
  • CO State Medical License
    CO State Medical License 2021 - 2023
  • Psychiatry
    American Board of Psychiatry and Neurology Psychiatry

Publications & Presentations

PubMed

Journal Articles

  • Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression  
    Lener MS, Kadriu B, Zarate C, Drugs, 2/14/2017

Authored Content

  • F173. Negative Trial of Scopolamine in Major Depressive Disorder Does Not Demonstrate Neurophysiological Changes Seen with the Antidepressant Response of KetamineApril 2018
  • F173. Negative Trial of Scopolamine in Major Depressive Disorder Does Not Demonstrate Neurophysiological Changes Seen with the Antidepressant Response of KetamineApril 2018

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: